Team USA walked away with five medals, including three silver and one bronze. The U.S. women’s foil team joined the history books in Paris after claiming Team USA’s first gold medal in the ...

Team USA walked away with five medals, including three silver and one bronze. The U.S. women’s foil team joined the history books in Paris after claiming Team USA’s first gold medal in the event with ...

From the outset of the Second World War, Australian women were aware of the changing role of British women in supporting Britain’s war effort. To help “do their bit” for Australia’s war effort, women ...

Suleiman Sandal, a prominent figure within the Sudanese Revolutionary Front (SRF), announced the proposal on Wednesday following a contentious debate within the Tagadum coalition, a broad alliance ...

In this article, we are going to take a look at where Teva Pharmaceutical Industries Limited (NYSE:TEVA) stands against other stocks that Jim Cramer discussed recently. As the Federal Reserve ...

Teva and Sanofi’s duvakitug achieved remission rates up to 47.8% in trials. The drug’s efficacy surpasses that of rivals like Merck and Roche in placebo-adjusted responses. The TL1A class ...

A significant proportion of subjects with UC who were treated with the therapy achieved clinical remission in the study. Credit: Wasan Tita/Shutterstock. Sanofi and Teva Pharmaceuticals have reported ...

Chesnot / Getty Images Teva Pharmaceuticals and Sanofi on Tuesday reported positive results in a Phase 2b trial of their drug for ulcerative colitis and Crohn's disease. The companies plan to ...

The anti-TL1A antibody allowed significantly more inflammatory bowel disease (IBD) patients to go into remission than those taking placebo treatment. Teva announced it was partnering with Sanofi to ...

Te­va and Sanofi an­nounced pos­i­tive mid-stage re­sults ahead of sched­ule for their in­flam­ma­to­ry bow­el dis­ease can­di­date as they look to keep pace in an an­ti … ...

Merck is working on the monoclonal antibody MK-7240—formerly known as PRA023—which it acquired in its $10.8 billion buyout of Prometheus Biosciences last year. In phase 2 results disclosed in ...